Form 4: 89bio, Inc. COO Receives Stock Options and Restricted Stock Units

Francis Sarena, Chief Operating Officer of 89bio, Inc., acquired stock options and restricted stock units on August 5, 2024.

Summary

• On August 5, 2024, Francis Sarena, the Chief Operating Officer of 89bio, Inc., received 350,000 stock options with an exercise price of $8.39.
• These options vest over time, with a quarter vesting on August 5, 2025, and the remainder vesting in equal quarterly installments through August 5, 2028, contingent upon continued service.
• Sarena also acquired 25,000 restricted stock units (RSUs) on the same date.
• A third of the RSUs vest on August 5, 2025, and the remaining two-thirds vest in equal installments every six months through August 5, 2027, also subject to continued service.
• Following these transactions, Sarena directly owns 350,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the executive's continued contribution.

Positives

• The grant of stock options and restricted stock units aligns the COO's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's long-term success.

Risks

• The value of the stock options is dependent on the future performance of 89bio, Inc.'s stock.
• If Sarena leaves the company before the options and RSUs fully vest, she will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule suggests an expectation of continued service and contribution from the COO.

Industry Context

Stock option and RSU grants are common practices in the biotechnology industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules are typically structured to align with long-term company goals, often spanning three to four years.
• The size of the grant is likely benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates